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2.3 Regional Update: Western Europe
Country/territory with reported 
injecting drug usea People who inject drugs
1
Adult HIV 
prevalence 
amongst 
people who 
inject drugs1
Harm reduction response2
NSPb OSTc DCRd 
Andorra nk nk x x x
Austria 17,500 7.1% (27) (B,M,O) x
Belgium 25,800 4.3% (34) (P) (B,H,M) x
Cyprus 305 0% (1) (P) (1) (B) x
Denmark 15,416 2.1% (135) (B,H,M) x
Finland 15,650 0.2% (52) (B,M) x
France 122,000 12.2% (416–2,014) (P) (19,484) (B,M,O) x
Germany 94,250 2.9% (250) (2,786–6,626) (B,H,M) 
Greece 9,720 0.5% (4) (P) (17) (B,M) x
Iceland nk nk x (B,M) x
Ireland 6,289 5.8% (33) (P) (332) (B,M) x
Italy 326,000 12.1%  (B,M) x
Luxembourg 1,715 2.8% (4) (B,M,H,O) 
Malta nk nk (7) (≥2) (B,M) x
Monaco nk nk x x x
Netherlands 3,115 9.5% (150) (P) (B,H,M) 
Norway 10,049 3.2% (22) (P) (B,M) 
Portugal 32,287 15.6% (27) (P) (B,M) x
Spain 83,972 39.7% (1,271–1,458) (P) (497–2,229) (B,H,M) 
Sweden nk 5.4% (2) (B,M) x
Switzerland 31,653 1.4% (101) (P) (B,H,M,O) 
Turkey nk 2.65% x x x
UK 156,398 2.3% (1,523) (P) (B,H,M) x
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Table 2.3.1: Harm reduction in Western Europe 
  Information on injecting drug use and harm reduction was not available for Liechtenstein and San Marino.a 
  The number in brackets represents the number of operational NSP sites, including fixed sites, vending b 
machines and mobile NSPs operating from a vehicle or through outreach workers. (P) = needles and syringes 
reported to be available for purchase from pharmacies or other outlets.
  The number in brackets represents the number of operational OST programmes, including publicly and c 
privately funded clinics and pharmacy dispensing programmes. (B) = buprenorphine, (H) = heroin-assisted 
treatment, (M) = methadone and (O) = any other form (including morphine and codeine).
  Drug consumption room (DCR).d 
nk = not known
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Harm Reduction in Western 
Europe
There are estimated to be approximately one million people 
who inject drugs in Western European countries.1 HIV prevalence 
among people who inject drugs is below 10%, with the exception 
of France, Italy, Portugal and Spain.1 Data show that Western 
European countries with good coverage of harm reduction 
programmes have seen ‘especially pronounced’ reductions 
in drug-related HIV transmission.3 For example, whereas in 
Switzerland in the 1980s the majority of new HIV diagnoses were 
among people who inject drugs, in 2008 this figure was only 4%; 
in the Netherlands the figure was 5% in 2007.3 Across the region, 
8% of new HIV diagnoses in 2007 were among people who inject 
drugs.4
Harm reduction forms an integral component of both HIV 
and drug policy and programmes in most Western European 
countries. It is also emphasised at the regional level in the 
European Union’s current drug strategy and action plan.5 6 In 
early 2010 almost every country with reported injecting drug use 
had key harm reduction interventions in place (the exceptions 
being Andorra, Monaco and Turkey). Several countries also 
include drug consumption rooms, syringe vending machines and 
the prescription of injectable opioid substitution therapy and 
diacetylmorphine (pharmaceutical heroin) among their harm 
reduction interventions. 
There remains much variation in harm reduction coverage. 
Some countries, such as Cyprus and Greece, currently reach 
low proportions of injecting populations with sterile injecting 
equipment and opioid substitution therapy (OST). Even within 
countries with long-established services, large areas are not 
covered and constraints on funding pose barriers to increasing 
access to these services. Furthermore, other drug-related health 
harms, such as viral hepatitis and overdose, remain leading 
causes of death among people who inject drugs. 
Many European governments provide bilateral support for harm 
reduction programmes in low- and middle-income countries 
and are among the most vocal in support of harm reduction in 
international fora. However, the ‘common position’ of EU states 
on harm reduction may be fragile and could waver, for example 
with changes in policies of member states. There is a need for 
increased civil society action, as well as continued government 
support, to keep Western Europe at the forefront of the harm 
reduction response. 
Developments in harm reduction 
implementation
Needle and syringe exchange programmes 
(NSPs)
The majority of states with reported injecting drug use in Western 
Europe have NSP sites. In 2010 the countries without NSPs, where 
injecting had been reported, were Andorra, Iceland, Monaco 
and Turkey. Various service delivery models are used across 
the region, including stand-alone sites, those situated within 
drugs services, pharmacy-based NSPs and outreach (including 
peer outreach), although not all are used in all countries. Some 
countries also have vending machinese and mobile NSP sites.7 
The latest available data indicate that the number of operational 
NSP sites varies widely from less than five in Cyprus (where only 
one site exists and it is yet to receive government endorsement), 
Sweden, Luxembourg and Greece to up to 1,458 in Spain and 
2,014 in France. The Netherlands is reported to have the most NSP 
sites per 1,000 people who inject drugs (50), followed by Spain 
(14.6) and the UK (10.7).8
Although data reporting systems are generally stronger in 
Western Europe than in most other regions, there is still a lack 
of available national data on the extent to which NSPs are 
utilised by people who inject drugs. This is partly due to a lack of 
harmonised indicators, incomplete information in some countries 
and an absence of reliable estimates of the prevalence of drug 
injecting.f 9
According to the information available, the highest utilisation 
figures are from Finland, where 81% of people who inject drugs 
accessed NSPs in a year, the equivalent of 13,000 people.2 
However, this is a poor indicator for HIV prevention, as it includes 
people that may have only visited once in a year.
A more informative measure is the rate of syringe distribution. 
Several countries are reported to distribute sterile injecting 
equipment to coverage levels nearing or above 200 syringes 
per person injecting drugs per year, as recommended by UN 
agencies.10 These include Norway, the country with the highest 
reported distribution in the world (434), Portugal (199), the UK 
(188) and Austria (176).2 
Western Europe is often cited as having high harm reduction 
coverage, particularly when compared with most low- and 
middle-income countries,11 12 however, there is substantial room 
for improvement.13 Several countries in this region have low 
NSP coverage, and even where higher coverage exists, funding, 
political support and legal restrictions often limit the service that 
can be provided.
Civil society organisations in the UK, for example, have recently 
engaged in a campaign for legal reform in order to allow the 
provision of foil for drug smoking at NSPs. Providing foil to 
people who inject drugs can be considered a route transition 
intervention, as it aims to encourage injectors to engage in less 
risky drug taking behaviour.14 Spanish and Dutch NSPs already 
provide this service, along with many in the UK, some of which 
have had ‘letters of comfort’ from local law enforcement bodies 
stating that workers will not be prosecuted. 
e  Austria, Denmark, France, Germany, Italy and Luxembourg.
f  More estimates are available for ‘problem drug use’, although definitions vary from country 
to country.
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A recent welcome development is the vote by Stockholm City 
Council to introduce NSPs into the city, expected by the end 
of 2010.15 Sweden has previously been criticised for its poor 
implementation of harm reduction measures, which in terms of 
needle and syringe provision consisted of two NSPs (neither in 
Stockholm) with 1,230 individual clients.2 A further limiting factor 
for people who inject drugs trying to obtain sterile injecting 
equipment is that syringe sales remain illegal in Sweden. 
Although the most recent systematic review by the Reference 
Group to the United Nations on HIV/AIDS and Injecting Drug Use 
found no reliable estimate of the number of injecting drug users 
in the country, the European Monitoring Centre on Drugs and 
Drug Addiction (EMCDDA) estimates there to be 26,000 people 
who use drugs problematically.g 16 
Drug consumption rooms (DCRs)
Drug consumption rooms are a largely European intervention 
and the region is home to all but two facilities worldwide. 
There are ninety operational DCRs across fifty-nine cities in 
the Netherlands, Germany, Luxembourg, Norway, Spain and 
Switzerland. These facilities, often part of another drug service, 
allow people to use drugs under the supervision of trained 
staff and without fear of arrest. Estimates show that these are 
well-utilised facilities, with tens of thousands of supervised 
consumptions reported in Luxembourg, Norway and in several 
German cities in 2007.17 No additional countries have adopted 
DCRs as part of their harm reduction approach since 2008.
Opioid substitution therapy (OST)
The provision of methadone or buprenorphine as maintenance 
therapy is a common approach across the region, with only 
Andorra, Monaco and Turkey not employing this harm reduction 
intervention. New data indicate that at least one OST site 
operates in Iceland, with fifteen people receiving methadone 
maintenance therapy (MMT), although it is not clear when it was 
introduced. Buprenorphine is also available, however, there is a 
lack of information on the numbers being reached.18 
In many Western European countries, the number of sites 
providing OST is not known. This may be partly due to the variety 
of service provision sites (including through general practitioners 
in France, Germany and the UK)19 and a lack of national systems 
to compile information. Where data are available, provision 
ranges from as little as one site in Cyprus and two sites in Malta to 
between 497 and 2,229 sites in Spain, between 2,786 and 6,626 
sites in Germany and 19,484 sites in France.8
The number of people receiving OST varies widely across the 
region, from small numbers in Iceland (fifteen people receiving 
MMT) and Cyprus (between nineteen and seventy-one people 
receiving buprenorphine from seven sites) to over 100,000 
people receiving various forms of OST in the UK, France and 
Italy.2 A recent analysis of OST coverage in European countries 
with estimates of the number of people with problem opioid use 
found that only Germany, Italy, Austria and Malta were meeting 
or exceeding the 40% deemed to be ‘high coverage’ by WHO, 
UNODC and UNAIDS.10 20 As in 2008, service access and uptake 
is limited by several factors, including strict policies and waiting 
lists for entry to programmes. In some countries, the cost to the 
individual acts as a barrier, as does the poor availability of ‘take-
home’ doses.9
g  The EMCDDA defines problem drug use as intravenous drug use or long duration/regular 
drug use of opiates, cocaine and/or amphetamines. Ecstasy and cannabis are not included in this 
category.
Western Europe offers a wider variety of OST options than other 
parts of the world. Almost all countries provide both methadone 
and buprenorphine for maintenance and some also offer slow-
release codeine. Others include injectable OST among their drug 
treatment options (for example, the UK, Switzerland and the 
Netherlands) and the use of heroin-assisted treatment (HAT) is 
becoming more common in the region (see table 2.3.1).
Heroin-assisted treatment
Seven Western European countries currently provide 
pharmaceutical heroin (diacetylmorphine) as maintenance 
therapy – Denmark, Germany, the Netherlands, Spain, 
Switzerland, the UK and, most recently, Belgium and 
Luxembourg (pilot programmes). Randomised controlled 
trials have found that this practice can reduce drug-related 
crime and health harms, with researchers concluding that 
it is both safe and cost-effective.21 22
Antiretroviral therapy (ART)  
Western Europe is reported to have the highest regional level 
of ART coverage among people who inject drugs in the world.2 
Data from thirteen countries (representing 46% of the total 
estimated HIV-positive injecting population in the region) 
suggest that eighty-nine in every 100 people living with HIV who 
inject drugs are receiving ART.2 National data is not available for 
every country, however, coverage varies widely: from Andorra (1 
person) to Germany (3,000) to Spain (39,524).
However, the EMCDDA reports that the relatively high numbers 
of people receiving AIDS diagnoses in Portugal and Spain (8.6 
and 8.8 new cases per million population respectively) may 
indicate that significant numbers of people who inject drugs are 
not benefiting from ART, possibly due to late diagnosis.20
Policy developments for harm 
reduction 
The vast majority of Western European countries include 
harm reduction in their national policies on HIV and/or drugs. 
A recent analysis found that at least twelve countries in the 
region specifically refer to harm reduction in their national drug 
policies.h 23 The authors describe national drug policies across 
Europe as occupying a ‘coordinated and increasingly coherent 
“middle ground” policy on drugs’, accepting harm reduction 
within a ‘recognisably shared approach’.23
In international fora, the EU has increasingly spoken with a unified 
voice on drug policy issues.23 For example, the EU played a key 
role in emphasising demand reduction within the negotiations 
on the new Political Declaration on Drugs at the High Level 
Segment of the Commission on Narcotic Drugs (CND) in 2009. 
Although explicit reference to harm reduction was struck from 
the final agreed text, the vast majority of the Western European 
delegations signed an ‘interpretative statement’ indicating 
their intention to interpret the term ‘related support services’ 
contained in the final declaration to include harm reduction 
services.24  
h  Belgium, Denmark, Germany, Ireland, Spain, France, Cyprus, Luxembourg, the Netherlands, 
Portugal, Finland and the UK. There is no national drug policy in Austria, instead policies exist at 
the provincial level.
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At the regional level, the EU’s drug strategy and action plan for 
2009 to 2012 emphasises harm reduction as a key component 
within the drug response. On evaluating progress on the 
previous action plan (2005 to 2008), which also included harm 
reduction, the European Commission (EC) concluded that ‘further 
improvements are still needed in [the] accessibility, availability 
and coverage’ of harm reduction services across the region.25 It 
also highlighted shortcomings of current responses in addressing 
the needs of subpopulations such as women, young people, 
migrants and specific ethnic groups.25 
While European policies in general include an emphasis on a 
public health approach to drugs, the region-wide consensus on 
harm reduction has the potential to be weakened. Government 
changes, financial crises and a continued emphasis on 
abstinence-based treatment and drug prevention programmes 
are factors that may cause the consensus to waver. For example, 
both Sweden and Italy do not include harm reduction in their 
national drug policies and, on occasion, have been less than 
supportive of the term in international fora.
NSP and OST appear to be accepted by most European drug 
policy makers, but a wider interpretation of harm reduction is not 
accepted by all, with DCRs and heroin prescription remaining the 
most controversial interventions. There is a continued need for 
government commitment to evidence-based drug policy in order 
for Europe to remain securely at the forefront of harm reduction. 
Civil society and advocacy 
developments for harm reduction
Civil society organisations have long been central to harm 
reduction advocacy in Western Europe and there have been 
several important developments in this regard. For example, 
the involvement of civil society representatives on CND 
delegations has increased. Representatives of the International 
Network of People Who Use Drugs (INPUD) and the International 
Harm Reduction Association (IHRA) have been part of the 
UK delegation in both 2009 and 2010 and a representative of 
the Transnational Institute was included in the Netherlands 
delegation in 2009. 
Regular national and Europe-wide events bring civil society 
organisations together to share latest experiences on harm 
reduction and drug policy. Over the past two years, region-wide 
events have included the 1st and 2nd Connections Conferences 
covering ‘Drugs, alcohol and criminal justice: Ethics, effectiveness 
and economics of interventions’ and the 2nd General Meeting of 
the Correlation Network (European Network on Social Exclusion 
and Health).
In July 2009 harm reduction advocates and frontline workers 
from Spain, France, Italy, Switzerland and the host country, 
Portugal, gathered for CLAT 5, the fifth Latin harm reduction 
conference, organised by APDES and Grup Igea.
National events addressing harm reduction are regularly held 
in several countries across the region. For example, Exchange 
Supplies hosts annual national conferences on injecting drug use 
and drug treatment, in Glasgow and London, which have a heavy 
harm reduction focus. 
Although civil society advocates for harm reduction have a 
voice in many Western European countries, there is a need 
to strengthen networks and partnerships across countries to 
facilitate the sharing of information and to inform policy at the 
national and regional levels. This is particularly important given 
recent indications of a fragmenting EU common position on harm 
reduction.
To this end, new networks have been established in recent 
months, for example EuroHRN, an EC-funded project involving 
six main partners and three further associate partners across the 
region. IHRA acts as the coordinator and secretariat for EuroHRN. 
The network has three sub-regional hubs covering north, south 
and east Europe, which will be hosted by Akzept (Germany) and 
FRG (the Netherlands), APDES (Portugal) and the Eurasian Harm 
Reduction Network (Lithuania) respectively.
As part of the two-year project, EuroHRN will advocate for harm 
reduction within Europe; facilitate cross-regional learning on 
harm reduction; establish the state of harm reduction in Europe, 
with a particular focus on civil society action; and develop and 
disseminate best practice models for the meaningful involvement 
of people who use drugs.
EuroHRN will be officially launched at the Harm Reduction 2010 
Conference in Liverpool in April 2010. The conference will also 
mark the first meeting of the recently formed Western European 
Network of People Who Use Drugs, which is aligned to INPUD. 
 
Danish Drug Users Union: BrugerForeningen
BrugerForeningen (BF) was set up in 1993 by a group of 
people who were receiving methadone. Initially it was 
a drop-in centre and meeting place used by twelve to 
fourteen people. By 2000, with a new venue and funding 
from the Ministry of Social Affairs, it had become a network 
with a membership of approximately 600 people receiving 
methadone. 
BF has worked in close collaboration with the national 
government. The BF president held a seat on the Danish 
government’s Narkotikaraadet, an expert national drug 
advisory council that operated between 1998 and 2002. 
BF has also worked with the local police on initiatives such 
as SyringePatrol, whereby used syringes were collected 
across Copenhagen.
BF continues to advocate for quality harm reduction 
services and to support drug users in accessing them. It is 
currently advocating for an amendment to the strict entry 
criteria for heroin-assisted treatment, a service introduced 
in Denmark in early 2010. 
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Multilaterals and donors: 
Developments for harm reduction 
Most support for harm reduction from multilateral agencies is 
not targeted towards the high-income countries of this region, 
but the EC has been an important donor for multi-country and 
international projects on drugs, including those related to harm 
reduction. For example, the EC has recently begun funding the 
Access to Opioid Medication in Europe (ATOME) project, a new 
consortium of scholars and public health specialists that will work 
to identify and remove the barriers in Europe preventing people 
from accessing critical opioid medications. This will include a 
substantial review of policies and legislation on opioid medicines 
in twelve European countries.26 As mentioned above, EuroHRN is 
also an EC-funded project. 
The WHO Regional Office for Europe continues to monitor HIV 
epidemics across the region, in collaboration with partners such 
as the European Centre for Disease Prevention and Control. In 
2008 the agency released a report monitoring state progress 
against targets set in the 2004 Dublin Declaration on Partnership 
to Fight HIV/AIDS in Europe and Central Asia, which contained a 
chapter specifically dedicated to people who inject drugs.19 The 
progress report found that among the worst implementation 
gaps were ‘instituting harm-reduction programmes and 
confronting other injecting drug user (IDU) issues.’19
Several European governments provide essential funds for 
harm reduction in low- and middle-income countries. These 
include the UK Department for International Development, 
the Netherlands MOFA, NORAD (Norway) GTZ (Germany) and 
Swedish SIDA. 
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